Categories: ImplantsNews

Sientra to Report Second Quarter 2023 Financial Results on August 10, 2023

IRVINE, Calif., July 27, 2023 (GLOBE NEWSWIRE) — Sientra, Inc. (NASDAQ: SIEN)(“Sientra” or the “Company”), a medical aesthetics company developing the safest and most innovative solutions for the best aesthetic outcomes, today announced that it will release financial results for the second quarter of 2023 after the close of trading on Thursday, August 10, 2023. Sientra will host a conference call to discuss financial results the same day at 4:30 p.m. Eastern Time.  

The dial-in numbers are (844) 735-3763 for domestic callers and (412) 317-5711 for international callers.

A live webcast of the conference call will be available on the Investor Relations section of the Company’s website at www.sientra.com. The webcast will be archived on the website following the completion of the call.

About Sientra

Headquartered in Irvine, California, Sientra is a medical aesthetics company focused on empowering people to change their lives through increased self-confidence and self-respect. Backed by unrivaled clinical and safety data, Sientra’s platform of products includes a comprehensive portfolio of round and shaped breast implants, the first fifth-generation breast implants approved by the FDA for sale in the United States, the ground-breaking AlloX2 breast tissue expander with patented dual-port and integral drain technology, the next-generation AlloX2Pro™, the first and only FDA-cleared MRI-compatible tissue expander, the Viality™ with AuraClens™ enhanced viability fat transfer system, the SimpliDerm Human Acellular Dermal Matrix, and BIOCORNEUM the #1 performing, preferred and recommended scar gel of plastic surgeons (*).

Sientra uses its investor relations website to publish important information about the Company, including information that may be deemed material to investors. Financial and other information about Sientra is routinely posted and is accessible on the Company’s investor relations website at www.sientra.com.

To learn more about Sientra, visit our website and follow Sientra on LinkedIn, Instagram, and Facebook.

(*) Data on file

Investor Relations Contact

Aman R. Patel, CFA
aman.patel@westwicke.com

 

Staff

Recent Posts

Poolbeg Pharma PLC Announces Notification of Major Holdings

LONDON, UNITED KINGDOM / ACCESSWIRE / July 10, 2024 / TR-1: Standard form for notification…

2 hours ago

Evotec and Pfizer Collaborate to Advance Drug Discovery in France

Multi-year collaboration will initially focus on early discovery research for metabolic and infectious diseases HAMBURG,…

2 hours ago

IRLAB Publishes Interim Report for the Period January-June 2024

GOTHENBURG, SWEDEN / ACCESSWIRE / July 10, 2024 / IRLAB Therapeutics (STO:IRLAB-A)(FRA:6IRA) Gothenburg, Sweden, July…

2 hours ago

AvodahMed Names Paul Wiley as President

WESTLAKE, Texas, July 9, 2024 /PRNewswire/ -- AvodahMed is pleased to announce the appointment of…

5 hours ago

HNL Lab Medicine Launches Digital Pathology Program

ALLENTOWN, Pa., July 9, 2024 /PRNewswire/ -- HNL Lab Medicine is excited to announce the…

5 hours ago

NuGen Develops Pharmacist Training Packages for the Canadian Retail Pharmacy Market

Toronto, Ontario--(Newsfile Corp. - July 9, 2024) - NuGen Medical Devices Inc. (TSXV: NGMD) (the…

11 hours ago